Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04030091 · ClinicalTrials.gov registry record · Phase 4
Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus
A Phase 4 study, sponsored by Sciema UG.
- Completed
- Registry status
- Phase 4
- Development phase
- 24
- Enrollment target
NCT04030091: Completed Phase 4 study, sponsored by Sciema UG.
NCT04030091 is a Phase 4 study that has completed, run by Sciema UG. The registered enrollment target is 24 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04030091, a Phase 4 study, has completed, sponsored by Sciema UG.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 24 participants
- Enrollment target
Study Summary
This study is an open label, prospective, randomised comparative, single center study. In the present study, the impact of a 12-week pulsatile insulin infusion therapy (PIT) with Humulin R 100 from
Primary Outcome
Impact of PIT on endothelial function before and one hour after the PIT initiation measured with the Vendys2 device
Interventions
- DRUG 3 hours humulin R 100 IU/mL PIT
- DRUG 2 hours humulin R 100 IU/mL PIT
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2019-09-06 |
| Est. Completion | 2020-12-31 |
| Phase | Phase 4 |
What the finished NCT04030091 record still lists
NCT04030091 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 2 interventions - of which 3 hours humulin R 100 IU/mL PIT is the first listed.
NCT04030091 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04030091 about?
NCT04030091 is a clinical study titled "Pulsatile Insulin Infusion Therapy in Patients With Type 1 and Type 2 Diabetes Mellitus". This study is an open label, prospective, randomised comparative, single center study. In the present study, the impact of a 12-week pulsatile insulin infusion therapy (PIT) with Humulin R 100 from
What is the current status of trial NCT04030091?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 24 participants. The study started on 2019-09-06. Estimated completion is 2020-12-31.
What interventions are being tested in trial NCT04030091?
The interventions under investigation include: 3 hours humulin R 100 IU/mL PIT (DRUG), 2 hours humulin R 100 IU/mL PIT (DRUG).
Who is sponsoring clinical trial NCT04030091?
This trial is sponsored by Sciema UG, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04030091's enrollment target sits among peer trials
24 1699th of 2000 higher than 276 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI